RNA interference (RNAi) is a remarkable natural cellular mechanism which regulates gene expression in a highly specific manner. In recent years, this process has become a vital tool in both fundamental research and drug development. Scientists use small molecules known as small interfering RNAs (siRNA) to selectively inhibit the expression of targeted genes. This has proven invaluable for understanding diseases, identifying therapeutic targets, and expediting the development of treatments, particularly in the context of genetic disease and cancer. However, harnessing the full potential of siRNA for therapeutic purposes faces challenges. The innate immune response tends to recognize those molecules as foreign, leading to their enzymatic degradation and/or activation of the immune system to eliminate them. To address these issues, researchers employ sophisticated chemical modifications to enhance siRNA stability, reduce immunogenicity, and improve efficacy. OligoTune Ltd is at the forefront of advancing this field with a pioneering approach to tackle solid tumours. In most cancers, the tumour evolves ways to hide from the immune system allowing it to grow and even spread to other organs. OligoTune's technology involves utilising several siRNAs capable of reshaping immune cells and awakening the immune system, providing a promising therapeutic avenue for the substantial proportion of solid tumour patients lacking viable treatment options. The present project undertaken by OligoTune focuses on developing a novel class of siRNA that can not only reprogram a cell but also directly stimulate the immune system to enhance the fight against cancer. The team is meticulously working on developing a chemically stabilised structure of these siRNAs, ensuring their potency and sustained effect on reprogramming immune cells, while incorporating stimulants which further activate the immune system. This dual-action approach enhances the therapeutic impact, fortifying the body's immune defence against tumours. This one-of-a-kind strategy could allow for further modulation of the immune cell activation and have therapeutic benefits in the treatment of cancer but also could be extended to other diseases like viral infection. In summary, OligoTune's innovative project integrates advanced siRNA modifications with immunostimulatory strategies to create a potent therapeutic intervention against cancer. This sophisticated approach holds promise for advancing cancer treatment and offers hope to a significant segment of patients bearing difficult to treat, immunosuppressive solid tumours.